New Delhi: The initial public offering (IPO) of Sai Life Sciences, a TPG-backed contract research, development, and manufacturing organization (CRDMO), is set to open its subscription process tomorrow, Wednesday, December 11. The firm, which provides comprehensive services throughout the entire drug discovery, development, and manufacturing process for small-molecule new chemical